Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 901–1,000 of 1,031
The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.
An, Y., Guan, Y., Xu, Y., Han, Y., Wu, C., Bao, C., Zhou, B., Wang, H., Zhang, M., Liu, W., et al. (2019) · Europe PMC (PubMed Central) · Cited by 52
Yaung, S. J., Fuhlbrück, F., Peterson, M., Zou, W., Palma, J. F., Patil, N. S., & Jiang, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00046 · Cited by 50
Anemia in older adults as a geriatric syndrome: A review
Katsumi, A., Abe, A., Tamura, S., & Matsushita, T. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14183 · Cited by 60
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
Babushok, D. V., Olson, T. S., & Bessler, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509703 · Cited by 48
Shared and distinct genetic etiologies for different types of clonal hematopoiesis
Brown, D. W., Cato, L. D., Zhao, Y., Nandakumar, S. K., Bao, E. L., Gardner, E. J., Hubbard, A. K., DePaulis, A., Rehling, T., Song, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41315-5 · Cited by 43
Wu, Q., Zhang, W., Lu, Y., Li, H., Yang, Y., Geng, F., Liu, J., Li, L., Pan, Y., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111558 · Cited by 47
The contribution of genetics and epigenetics to MAFLD susceptibility
Moretti, V., Romeo, S., & Valenti, L. V. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10667-5 · Cited by 53
Aging as a driver of leukemogenesis
McKerrell, T., & Vassiliou, G. S. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4428 · Cited by 48
Criado, I., Rodríguez‐Caballero, A., Gutiérrez, M. L., Pedreira, C. E., Alcoceba, M., Nieto, W. G., Teodósio, C., Bárcena, P., Romero, A. E., Fernández-Navarro, P., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183954 · Cited by 47
Somatic mutations in the human brain: implications for psychiatric research
Nishioka, M., Bundo, M., Iwamoto, K., & Kato, T. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0129-y · Cited by 50
Clonal Hematopoiesis and Its Impact on Cardiovascular Disease
Sano, S., Wang, Y., & Walsh, K. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0871 · Cited by 47
Gut microecology: Why our microbes could be key to our health
Lu, D., Huang, Y., Kong, Y., Tao, T., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110784 · Cited by 49
Rummelt, C., Gorantla, S. P., Meggendorfer, M., Charlet, A., Endres, C., Döhner, K., Heidel, F. H., Fischer, T., Haferlach, T., Duyster, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01077-1 · Cited by 49
Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells
Wang, Q., Liu, Y., Wang, H., Jiang, P., Qian, W., You, M., Han, Y., Zeng, X., Li, J., Lu, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33410-w · Cited by 51
Stem cell mutations, associated cancer risk, and consequences for regenerative medicine
Derks, L. L. M., & van Boxtel, R. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.008 · Cited by 49
Ottaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 50
“Somatic mutations in genes encoding for epigenetic modi fi ers (TET2, DNMT3A, ASXL1) have been identi fi ed as potential drivers of clonal haematopoiesis (CH) [76 – 79] and are associated with increased risks of blood cancers [80].”
Bartels, S., Schipper, E., Hasemeier, B., Kreipe, H. H., & Lehmann, U. (2016) · Oncotarget · doi:10.18632/oncotarget.8310 · Cited by 47
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Hirsch, P., Tang, R., Abermil, N., Flandrin‐Gresta, P., Moatti, H., Favale, F., Suner, L., Lorre, F., Marzac, C., Fava, F., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159681 · Cited by 47
Parkin, B. L., Londoño-Joshi, A. I., Kang, Q., Tewari, M., Rhim, A. D., & Malek, S. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91964 · Cited by 48
Furuki, H., Yamada, T., Takahashi, G., Iwai, T., Koizumi, M., Shinji, S., Yokoyama, Y., Takeda, K., Taniai, N., & Uchida, E. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.01.224 · Cited by 47
Grimm, J., Bill, M., Jentzsch, M., Beinicke, S., Häntschel, J., Goldmann, K., Schulz, J. C., Cross, M. A., Franke, G., Behre, G., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0413-0 · Cited by 49
“CHIP correlated with an increased risk of developing a hematologic malignancy as well as atherosclerotic cardiovascular disease and higher all-cause mortality [2, 5, 8].”
BackgroundGenetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease
Martignoles, J., Delhommeau, F., & Hirsch, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123850 · Cited by 52
“Some mutations, including those in DNMT3A, TET2, and ASXL1, have been shown to appear years before the occurrence of AML [6].”
BackgroundInfluentialClonal hematopoiesis: Pre-cancer PLUS
Silver, A. J., & Jaiswal, S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.003 · Cited by 51
Somatic Variants: New Kids on the Block in Human Immunogenetics
Horebeek, L. V., Dubois, B., & Goris, A. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.09.005 · Cited by 48
Kiefer, K. C., Cremer, S., Pardali, E., Aßmus, B., Abou‐El‐Ardat, K., Kirschbaum, K., Dorsheimer, L., Rasper, T., Berkowitsch, A., Serve, H. L., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13297 · Cited by 49
Wei, H., Li, A., Liu, Y., Xiao, X., Christiani, D. C., Hung, R. J., McKay, J., Field, J. K., Amos, C. I., & Cheng, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1903 · Cited by 48
Wu, J., Zhang, Y., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Jia, Y., Li, C., Wang, H., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00328-4 · Cited by 51
Dillon, L. W., Higgins, J., Nasif, H., Othus, M. K. D., Beppu, L. W., Smith, T. H., Schmidt, E. K., Valentine, C. C., Salk, J. J., Wood, B. L., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283520 · Cited by 46
“…previously established, clinically relevant variant filtering conditions, including VAF thresholds well above the assay limit of detection and removal of less informative genes ( DNMT3A , TET2 , ASXL1 ) associated with clonal hematopoiesis, 24,25 was highly predictive of adverse clinical outcomes.”
BackgroundLymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
von Beck, K., von Beck, T. A., Ferrell, P. B., Bick, A. G., & Kishtagari, A. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00773-8 · Cited by 55
Hong, T., Li, J., Guo, L., Cavalier, M., Wang, T., Dou, Y., de-la-Fuente, A. L. C., Fang, S., Guzman, A. G., Wohlan, K., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00505-y · Cited by 51
“Our findings shed light on how two epigenetic enzymes, which control DNA methylation in the opposite directions and are often mutated in patients with CH and hematological neoplasms 15–17 , can produce similar clonal expansion phenotypes in HSPCs.”
BackgroundThe Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
Abou‐El‐Enein, M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0272 · Cited by 48
Cazzola, M., & Malcovati, L. (2015) · Hematology · doi:10.1182/asheducation-2015.1.19 · Cited by 47
Buscarlet, M., Tessier, A., Provost, S., Mollica, L. R., & Busque, L. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.07.009 · Cited by 45
The emerging significance of secondary germline testing in cancer genomics
Mandelker, D. L., & Zhang, L. (2018) · The Journal of Pathology · doi:10.1002/path.5031 · Cited by 45
Berger, G., Kroeze, L. I., Koorenhof‐Scheele, T. N., de Graaf, A. O., Yoshida, K., Ueno, H., Shiraishi, Y., Miyano, S., van den Berg, E., Schepers, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805879 · Cited by 45
Circulating Tumor DNA for Early Cancer Detection
Fiala, C., Kulasingam, V., & Diamandis, E. P. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.026393 · Cited by 45
Transposable Element Expression in Acute Myeloid Leukemia Transcriptome and Prognosis
Colombo, A., Triche, T. J., & Ramsingh, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-34189-x · Cited by 45
Mechanisms of leukemic transformation in congenital neutropenia
Link, D. C. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000479 · Cited by 46
A brief, but comprehensive, guide to clonal evolution in aplastic anemia
Babushok, D. V. (2018) · Hematology · doi:10.1182/asheducation-2018.1.457 · Cited by 48
“32 (2003) Prospective: ATG, with or without CsA 94 32 (2-80) 11 5 10 (11) 4 8 (11)”
InfluentialJakubek, Y. A., Chang, K., Sivakumar, S., Yu, Y., Giordano, M. R., Fowler, J., Huff, C., Kadara, H. N., Vilar, E., & Scheet, P. A. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0297-6 · Cited by 50
Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia
Yang, F., Anekpuritanang, T., & Press, R. D. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00443-9 · Cited by 51
Wilhelmson, A. S., & Porse, B. T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16534 · Cited by 48
What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics
Steensma, D. P., & Bolton, K. L. (2020) · Blood · doi:10.1182/blood.2019004291 · Cited by 14
Castiglione, M. A., Jiang, Y., Mazzeo, C., Lee, S., Chen, J., Kaushansky, K., Yin, W., Lin, R. Z., Zheng, H., & Zhan, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15095 · Cited by 48
“60 To help explain the molecular mechanism(s) by which the JAK2V617F mutation alters endothelial function to promote cardiovascular complications in MPNs, we found that: (1) the key endothelial function regulators KLF2, KLF4, TM, and eNOS levels were significantly down regulated in JAK2V617F-mutant ECs compared to wil…”
Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Feusier, J. E., Arunachalam, S., Tashi, T., Baker, M. J., Vansant-Webb, C. H., Ferdig, A., Welm, B. E., Rodríguez-Flores, J. L., Ours, C., Jorde, L. B., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0094 · Cited by 48
“Clonal hematopoiesis of indeterminate potential (CHIP), which is detected as an expansive clonal somatic mutation in a person currently free from hematologic malignancy, carries a greatly increased risk (HR >10) for future blood cancer development (5, 6).”
BackgroundAge acquired skewed X chromosome inactivation is associated with adverse health outcomes in humans
Roberts, A. L., Morea, A., Amar, A., Zito, A., Moustafa, J. S. E.-S., Tomlinson, M., Bowyer, R. C. E., Zhang, X., Christiansen, C., Costeira, R., et al. (2022) · eLife · doi:10.7554/elife.78263 · Cited by 46
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
Diamond, B. T., Ziccheddu, B., Maclachlan, K. H., Taylor, J., Boyle, E. M., Ossa, J. A., Jahn, J., Affer, M., Totiger, T. M., Coffey, D. G., et al. (2023) · Blood · doi:10.1182/blood.2022018244 · Cited by 65
Li, C., Shao, J., Li, P., Feng, J., Li, J., & Wang, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216365 · Cited by 50
Rai, S., Zhang, Y., Grockowiak, É., Kimmerlin, Q., Hansen, N., Stoll, C. B., Usart, M., Paz, D. L., Hao-Shen, H., Zhu, Y., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011338 · Cited by 48
“JAK2-V617F is the most frequent driver gene mutation in patients with MPN, but JAK2-V617F can also be detected as "clonal hematopoiesis of indeterminate potential" (CHIP) in healthy individuals, with a frequency much higher than the incidence of MPN (10-13).”
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays
Lee, J., Cho, E. H., Kim, B., Hong, J., Kim, Y., Kim, Y., Jang, J., Lee, S., Kong, S., Lee, W., et al. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0389 · Cited by 52
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche
Winter, S., Götze, K. S. S., Hecker, J. S., Metzeler, K. H., Guezguez, B., Woods, K., Medyouf, H., Schäffer, A., Schmitz, M., Wehner, R., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02226-6 · Cited by 50
“Such clonal expansion becomes increasingly detectable with age with divergent health implications [6, 7].”
BackgroundDefining precancer: a grand challenge for the cancer community
Faupel‐Badger, J. M., Kohaar, I., Bahl, M., Chan, A. T., Campbell, J. D., Ding, L., Marzo, A. M. D., Maitra, A., Merrick, D. T., Hawk, E. T., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00744-0 · Cited by 46
“and some lymphomas 49,50 , indicating that these clones may progress to overt malignancies.”
Robertson, A. L., Avagyan, S., Gansner, J. M., & Zon, L. I. (2016) · FEBS Letters · doi:10.1002/1873-3468.12415 · Cited by 45
The epigenetic basis of hematopoietic stem cell aging
Kramer, A. C., & Challen, G. A. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.006 · Cited by 50
Meggendorfer, M., Cappelli, L. V., Walter, W., Haferlach, C., Kern, W., Falini, B., & Haferlach, T. (2018) · Leukemia · doi:10.1038/s41375-018-0026-z · Cited by 47
Dillon, L. W., Hayati, S., Roloff, G. W., Tunc, I., Pirooznia, M., Mitrofanova, A., & Hourigan, C. S. (2018) · Haematologica · doi:10.3324/haematol.2018.203133 · Cited by 44
“For example, mutations found in preleukemic founder clones can persist at significant levels even during complete remission(8-11) and have also been observed in healthy individuals without hematologic malignancies with increasing age.(12-15) To help harmonize AML MRD detection efforts, the European LeukemiaNet (ELN) r…”
BackgroundPalomo, L., Ibáñez, M., Abáigar, M., Vázquez, I., Álvarez, S., Cabezón, M., Tazón‐Vega, B., Rapado, I., Fuster‐Tormo, F., Cervera, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16175 · Cited by 53
“The incidence of CHIP increases with age, with more than 10% of healthy people older than 70 years of age carrying a mutation in one of those genes (Genovese et al, 2014; Jaiswal et al, 2014).”
BackgroundDnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis
Zhang, X., Wang, X., Wang, X. Q. D., Su, J., Putluri, N., Zhou, T., Qu, Y., Jeong, M., Guzman, A. G., Rosas, C., et al. (2020) · Blood · doi:10.1182/blood.2019003330 · Cited by 45
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia
Li, J., Dai, Y., Wu, L., Zhang, M., Ouyang, W., Huang, J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0821-6 · Cited by 50
Modeling and targeting of erythroleukemia by hematopoietic genome editing
Iacobucci, I., Qu, C., Varotto, E., Janke, L. J., Xu, Y., Seth, A., Shelat, A. A., Friske, J. D., Fukano, R., Yu, J., et al. (2021) · Blood · doi:10.1182/blood.2020009103 · Cited by 48
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy
Kanagal‐Shamanna, R., Beck, D. B., & Calvo, K. R. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-122724 · Cited by 51
Busque, L., Porwit‐MacDonald, A., Day, R., Olney, H. J., Leber, B. F., Éthier, V., Sirhan, S., Foltz, L., Prchal, J. F., Kamel‐Reid, S., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw131 · Cited by 47
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
Dombret, H., & Itzykson, R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.45 · Cited by 46
“‡Three or more unrelated chromosome abnormalities in the absence of one of the WHO-designated recurring translocations or inversions [ie, t(8,21), inv(16); t(16,16), t(9,11), t(v,11)(v,q23.”
BackgroundConcordance for clonal hematopoiesis is limited in elderly twins
Fabre, M. A., McKerrell, T., Zwiebel, M., Vijayabaskar, M. S., Park, N., Wells, P. M., Rad, R., Deloukas, P., Small, K., Steves, C. J., et al. (2020) · Blood · doi:10.1182/blood.2019001807 · Cited by 43
Immunometabolic control of hematopoiesis
Hajishengallis, G., Li, X., & Chavakis, T. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100923 · Cited by 48
Mosteo, L., Storer, J. A., Batta, K., Searle, E. J., Duarte, D., & Wiseman, D. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.635189 · Cited by 45
“Incidence of CHIP is intimately linked to age, being found in <1% of individuals below 50 years but rising sharply to >20% of individuals in their tenth decade (Genovese et al., 2014; Jaiswal et al., 2014).”
BackgroundMyelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Tefferi, A., Gangat, N., Pardanani, A. D., & Crispino, J. D. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2930 · Cited by 48
“6 individuals has added to the complexity regarding their precise pathogenetic contribution.(66,67) More recent”
BackgroundClonal hematopoiesis: Molecular and clinical implications
Kusne, Y. N., Xie, Z., & Patnaik, M. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106787 · Cited by 47
CHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression
Liu, X., Sato, N., Shimosato, Y., Wang, T., Denda, T., Chang, Y., Yabushita, T., Fujino, T., Asada, S., Tanaka, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15294 · Cited by 43
Clonal haematopoiesis, ageing and kidney disease
Vlasschaert, C., Lanktree, M. B., Rauh, M. J., Kelly, T. N., & Natarajan, P. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00778-x · Cited by 43
“However, somatic mosaicism is also observed in healthy tissue across organ systems 4–9 , as well as non-cancerous and pre-cancerous states in the continuum of healthy to malignant tissue 10 , including in VEXAS syndrome 11 , endometriosis 12 and clonal haematopoiesis 13,14 .”
Yu, K., Deuitch, N. T., Merguerian, M., Cunningham, L., Davis, J., Bresciani, E., Diemer, J. L., Andrews, E. T., Young, A., Donovan, F. X., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011165 · Cited by 47
“42 We set out to determine the frequency of CH in our cohort by comparing our data with those of the population cohort reported by the Trans-Omics for Precision Medicine (TOPMed) research program.”
ResultDynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Arends, C. M., Kopp, K., Hablesreiter, R., Estrada, N., Christen, F., Moll, U. M., Zeillinger, R., Schmitt, W., Sehouli, J., Kulbe, H., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02253-3 · Cited by 50
“…(CH), characterized by the expansion of somatically mutated hematopoietic stem cells, has emerged as a prevalent phenomenon associated with the development of hematologic malignancies [1 – 4], increased cardiovascular risk [5, 6] and other age-related pro-in fl ammatory conditions [7 – 11].”
BackgroundHematopoietic Stem Cells and Their Niche in Bone Marrow
Kwon, M., Kim, B. S., Yoon, S., Oh, S., & Lee, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136837 · Cited by 47
“This phenomenon becomes increasingly common with age and is associated with a higher risk of hematologic malignancies and cardiovascular diseases [41,50,51].”
BackgroundMohamedali, A. M., Gäken, J. A., Ahmed, M., MALIK, F., Smith, A., Best, S., Mian, S. A., Gaymes, T. J., Ireland, R. M., Kulasekararaj, A. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.110 · Cited by 45
Increased DNA methylation of Dnmt3b targets impairs leukemogenesis
Schulze, I., Rohde, C., Scheller, M., Bäumer, N., Krause, A., Herbst, F., Riemke, P., Hebestreit, K., Tschanter, P., Lin, Q., et al. (2016) · Blood · doi:10.1182/blood-2015-07-655928 · Cited by 47
“DNMT3A mutations are also the most common finding in clonal hematopoiesis in older adults.(69) These seemingly contradictory findings prompted us to evaluate the functional consequences of high de novo Dnmt activity in leukemogenesis.”
BackgroundA novel class of somatic mutations in blood detected preferentially in CD8 + cells
Valori, M., Jansson, L., Kiviharju, A., Ellonen, P., Rajala, H. L. M., Awad, S. A., Mustjoki, S. M., & Tienari, P. J. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.11.018 · Cited by 48
“10–20% in whole exome sequence data [3] or in a set of 160 genes implicated in hematologic cancers [4].”
BackgroundMethodIncidence and survival of therapy related myeloid neoplasm in United States
Murthy, G. S. G., Hamadani, M., Dhakal, B., Hari, P., & Atallah, E. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.013 · Cited by 45
The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia
Zheng, G., Chen, P., Pallavajjalla, A., Haley, L. M., Gondek, L. P., Dezern, A. E., Ling, H., Marchi, F. D., Lin, M., & Gocke, C. D. (2019) · American Journal of Hematology · doi:10.1002/ajh.25592 · Cited by 43
“In contrast, mutations of factors involving DNA methylation, especially TET2 and DNMT3A, do occur in both AA and cytopenia groups, supporting the presence of clonal hematopoiesis of indeterminate potential (CHIP).(20,21,36-38) Furthermore, in this cohort, somatic mutations involving SRSF2, RUNX1, U2AF1, ZRSR2, CBL, ID…”
BackgroundMutations in normal tissues—some diagnostic and clinical implications
Fiala, C., & Diamandis, E. P. (2020) · BMC Medicine · doi:10.1186/s12916-020-01763-y · Cited by 46
“A landmark study of 12,380 patients elucidated some of the clinical implications of clonal hematopoiesis [40].”
BackgroundInfluentialCai, Z., Lu, X., Zhang, C., Nelanuthala, S., Aguilera, F., Hadley, A., Ramdas, B., Fang, F., Nephew, K., Kotzin, J. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140707 · Cited by 42
“Not only are TET2 mutations prevalent in healthy elderly individuals manifesting ARCH, but TET2 is also one of the most highly mutated genes in MPNs, chronic myelomonocytic leukemia (CMML), myelodysplasia syndrome (MDS), secondary acute myeloid leukemia (AML), and de novo AML (3, 4).”
BackgroundAndersson, D., Kristiansson, H., Kubista, M., & Ståhlberg, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1889371 · Cited by 43
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 46
The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time
Huber, A. R., van Hoeck, A., & van Boxtel, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.760039 · Cited by 43
“The incidence of CH is higher in elderly individuals and was initially detected by somatic mutations in DNMT3A, ASXL1, and TET2 (Genovese et al., 2014; Jaiswal et al., 2014).”
BackgroundHuber, S., Haferlach, T., Meggendorfer, M., Hütter, S., Hoermann, G., Baer, C. R., Kern, W., & Haferlach, C. (2022) · Leukemia · doi:10.1038/s41375-022-01728-5 · Cited by 45
The International Consensus Classification of myelodysplastic syndromes and related entities
Hasserjian, R. P., Orazi, A., Órfão, A., Rozman, M., & Wang, S. A. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03417-1 · Cited by 47
“Population studies have shown that CH in individuals with normal blood counts, termed clonal hematopoiesis of indeterminate potential (CHIP), increases with age [1, 2].”
BackgroundHansen, J. W., Westman, M. K., Sjø, L. D., Saft, L., Kristensen, L. S., Ørskov, A. D., Treppendahl, M. B., Andersen, M. K., & Grønbæk, K. (2016) · American Journal of Hematology · doi:10.1002/ajh.24554 · Cited by 42
“This is emphasized by the fact that asymptomatic patients have a significantly increased risk of developing hematological cancer when the allelic burden of mutations is above 10% [8,13].”
BackgroundSomatic variation in normal tissues: friend or foe of cancer early detection?
Acha‐Sagredo, A., Ganguli, P., & Ciccarelli, F. D. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.156 · Cited by 44
Homan, C. C., Drazer, M. W., Yu, K., Lawrence, D., Feng, J., Arriola‐Martinez, L., Pozsgai, M. J., McNeely, K. E., Ha, T., Venugopal, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010045 · Cited by 47
“…most signi fi cant risk factor for CH in the general population is aging, with ~10% of individuals over the age of 70 years having detectable CH. 32,33 Several studies investigating CH in the background of inherited bone marrow failure have shown an increased risk for CH. 34,40,41 Interestingly,…”
BackgroundClonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View
Sikking, M. A., Stroeks, S. L. V. M., Waring, O. J., Henkens, M. T. H. M., Riksen, N. P., Hoischen, A., Heymans, S. R. B., & Verdonschot, J. A. J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030603 · Cited by 44
“CHDMs are most commonly found in genes encoding epigenetic enzymes (eg, DNMT3A , TET2 , and ASXL1 ), signaling proteins (eg, JAK2 ), 3,4,37 spliceosome components (eg, SRSF2 and SF3B1 ), or members of the DNA damage response (eg, PPM1D and TP53 ).”
Morganti, S., Gibson, C. J., Jin, Q., Santos, K., Patel, A., Wilson, A., Merrill, M. S., Vincuilla, J., Stokes, S., Lipsyc-Sharf, M. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01071 · Cited by 46
Reinig, E. F., Yang, F., Traer, E. A., Arora, R., Brown, S., Rattray, R. M., Braziel, R. M., Fan, G., Press, R. D., & Dunlap, J. B. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw016 · Cited by 41
“Low-level gene mutations have recently been described in persons without overt evidence of a hematologic malignancy.(22,23) These mutations increase in frequency with age; most often involve DNMT3A, TET2, and ASXL1 and confer an increased risk for development of a hematologic”
BackgroundMinimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
Käyser, S., Walter, R. B., Stock, W., & Schlenk, R. F. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0260-7 · Cited by 41
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
Martinelli, G., Mancini, M., Benedittis, C. D., Rondoni, M., Papayannidis, C., Manfrini, M., Meggendorfer, M., Calogero, R., Guadagnuolo, V., Fontana, M. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.183 · Cited by 45
Methods of Detection of Measurable Residual Disease in AML
Zhou, Y., & Wood, B. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0419-5 · Cited by 41
The prevalence of germline DICER1 pathogenic variation in cancer populations
Kim, J., Schultz, K. A. P., Hill, D. A., & Stewart, D. R. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.555 · Cited by 43
“Another possibility is age‐related somatic variation, commonly observed in TP53 as clonal hematopoiesis (Genovese et al., 2014).”
Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies
Jiang, P., Chan, K. C. A., & Lo, Y. M. D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.003 · Cited by 44
Coffee, B. W., Cox, H. C., Bernhisel, R., Manley, S., Bowles, K. R., Roa, B. B., & Mancini‐DiNardo, D. (2019) · Human Mutation · doi:10.1002/humu.23910 · Cited by 43
“This demonstrates that the PV is not present in all tissues; however, it remains undetermined whether the PV is restricted to blood (CHIP) or is present in some but not all tissues (constitutional mosaic).”
BackgroundInfluentialMaia, C., Puig, N., Cedena, M., Goicoechea, I., Valdés‐Mas, R., Vázquez, I., Chillón, C., Aguirre‐Ruiz, P., Sarvide, S., Gracia-Aznárez, F. J., et al. (2020) · Blood · doi:10.1182/blood.2019003382 · Cited by 44
Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marando, L., & Huntly, B. J. P. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00918-7 · Cited by 49
Li, J., Jiang, W., Wei, J., Zhang, J., Cai, L., Luo, M., Wang, Z., Sun, W., Wang, S., Wang, C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02449-y · Cited by 43
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.